Drug Guidance
Talquetamab for relapsed or refractory multiple myeloma
Condition
Blood and Immune System
Cancer
6 February 2026
-
Published on 06 Feb 2026
Last Updated on 06 Feb 2026
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has not recommended talquetamab for inclusion on the MOH List of Subsidised Drugs for treating relapsed or refractory multiple myeloma in patients who have received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent, and an anti-cluster of differentiation 38 antibody, and have demonstrated disease progression on the last therapy. The decision was based on the uncertainty surrounding the extent of talquetamab’s comparative effectiveness, unacceptable cost effectiveness compared with physician’s choice of treatment, and the unacceptable price-volume agreement proposed by the company.
Clinical indication, subsidy class and MediShield Life claim limit for talquetamab are provided in the Annex.
Guidance_Talquetamab for relapsed or refractory multiple myeloma (6 Feb 2026)
PES_Talquetamab for relapsed or refractory multiple myeloma (6 Feb 2026)